Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.54 |
| ▸ | HTR6 | P50406 | 7/20 | 0.42 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR7 | P34969 | 3/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015927 | 0.79 | TRPV1 (0.55) | TRPV1HTR6EHMT2EHMT1 | |
| SCHEMBL15534340 | 0.74 | HTR6 (0.51) | HTR6HTR1ADRD2HTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL15548697 | 0.73 | HTR6 (0.53) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL1011898 | 0.72 | TRPV1 (0.51) | TRPV1PDE10A | |
| SCHEMBL1013567 | 0.71 | TRPV1 (0.58) | TRPV1CYP1A2CYP3A4DDB1CRBN | |
| SCHEMBL14108441 | 0.71 | TRPV1 (0.61) | TRPV1CYP1A2 | |
| SCHEMBL1012912 | 0.71 | TRPV1 (0.58) | TRPV1CYP1A2DDB1CRBN | |
| SCHEMBL13868105 | 0.70 | TRPV1 (1.00) | TRPV1ABL1BCR | |
| SCHEMBL15486423 | 0.69 | USP2 (0.62) | CYP1A2CYP3A4CDK9CCNT1EHMT2 | |
| SCHEMBL4832759 | 0.68 | TRPV1 (0.87) | TRPV1ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542692-B1 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7396831-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396831-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396831-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7053088-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050277646-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050267163-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-01 | — | — | US | disclosed |
| EP-1542692-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | Amgen Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003099284-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885HTR6 140/4885HTR1A 91/4885 |
| US-20050267163-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885HTR6 133/4885HTR1A 117/4885 |
| US-20050277646-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885HTR6 133/4885HTR1A 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.